Fu X - Search Results

1

A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.

Fu X, Meng F, Tao L, Jin A, Zhang X. Fu X, et al. Gene Ther. 2003 Aug;10(17):1458-64. doi: 10.1038/sj.gt.3302029. Gene Ther. 2003. PMID: 12900760

2

Isomerization of a uniquely designed amplicon during herpes simplex virus-mediated replication.

Wang H, Fu X, Zhang X. Wang H, et al. Among authors: fu x. J Virol. 2001 Nov;75(21):10505-10. doi: 10.1128/JVI.75.21.10505-10510.2001. J Virol. 2001. PMID: 11581421 Free PMC article.

3

Delivery of herpes simplex virus vectors through liposome formulation.

Fu X, Zhang X. Fu X, et al. Mol Ther. 2001 Nov;4(5):447-53. doi: 10.1006/mthe.2001.0474. Mol Ther. 2001. PMID: 11708881 Free article.

4

An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.

Fu X, Tao L, Zhang X. Fu X, et al. Cancer Gene Ther. 2007 May;14(5):480-7. doi: 10.1038/sj.cgt.7701033. Epub 2007 Feb 9. Cancer Gene Ther. 2007. PMID: 17290283

5

An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells.

Fu X, Tao L, Zhang X. Fu X, et al. Gene Ther. 2007 Aug;14(16):1218-25. doi: 10.1038/sj.gt.3302971. Epub 2007 May 31. Gene Ther. 2007. PMID: 17538637

6

Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity.

Fu X, Tao L, Rivera A, Xu H, Zhang X. Fu X, et al. Cancer Gene Ther. 2011 Nov;18(11):785-94. doi: 10.1038/cgt.2011.46. Epub 2011 Aug 26. Cancer Gene Ther. 2011. PMID: 21869820 Free PMC article.

7

Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma.

Cui Y, Li X, Sun Z, Leng C, Young K, Wu X, Zhang L, Fu X, Li L, Zhang X, Chang Y, Nan F, Li Z, Yan J, Zhou Z, Zhang M, Li W, Wang G, Zhang D. Cui Y, et al. Among authors: fu x. Leuk Lymphoma. 2015;56(9):2613-8. doi: 10.3109/10428194.2015.1014366. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25676238

8

The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.

Li L, Duan W, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Zhang X, Chang Y, Nan F, Yan J, Li Z, Young KH, Zhang M. Li L, et al. Among authors: fu x. Br J Haematol. 2017 Sep;178(5):772-780. doi: 10.1111/bjh.14763. Epub 2017 Jun 9. Br J Haematol. 2017. PMID: 28597542 Free article. Clinical Trial.

9

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.

Zhang L, Jia S, Ma Y, Li L, Li X, Wang X, Fu X, Ma W, Qin Y, Li W, Wu J, Sun Z, Zhang X, Nan F, Chang Y, Li Z, Zhang D, Wang G, Yan J, Su L, Wang J, Xue H, Young KH, Zhang M. Zhang L, et al. Among authors: fu x. Oncotarget. 2016 Aug 23;7(34):55721-55731. doi: 10.18632/oncotarget.10124. Oncotarget. 2016. PMID: 27384676 Free PMC article. Clinical Trial.

10

MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1.

Chang Y, Cui M, Fu X, Zhang L, Li X, Li L, Wu J, Sun Z, Zhang X, Li Z, Nan F, Yan J, Zhang M. Chang Y, et al. Among authors: fu x. Cancer Biol Ther. 2019;20(1):31-41. doi: 10.1080/15384047.2018.1504721. Epub 2018 Oct 9. Cancer Biol Ther. 2019. PMID: 30299211 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,652 results

Search Page

Filters